Encore Dermatology focuses on developing domestic prescription dermatology products for patients... Read more
Encore Dermatology focuses on developing domestic prescription dermatology products for patients... Read more
News
Apr 09, 2019
FinSMEs
Encore: Encore Dermatology Receives $20M Venture Loan Facility from Horizon Technology Finance
Apr 03, 2019
India Infoline
Encorederm: Dr Reddys arm sells US rights for 3 brands to Encore Dermatology
Apr 02, 2019
BioSpace
Encorederm: Encore Dermatology Inc. Acquires SERNIVO®, TRIANEX® and PROMISEB®
Apr 02, 2019
Pharmabiz
Encorederm: Dr. Reddy's sells Sernivo; grants Promiseb and Trianex US marketing rights to Encore Dermatology
Jan 30, 2019
4-traders
Encorederm: Encore Dermatology Inc. : Announces Results From Pivotal Study Evaluating Impoyz (clobetasol propionate) Cream, 0.025% for the Treatment of Moderate to Severe Plaque Psoriasis
Nov 27, 2018
PharmiWeb
Encorederm: Encore Dermatology, Inc. Announces Phase 2 Safety Data Demonstrating Lower Systemic Drug Exposure With Impoyz (clobetasol propionate) Cream, 0.025% Compared to Temovate® (clobetasol propionate) Cream, 0.05%
Oct 14, 2018
BioPortfolio
Encorederm: Encore Dermatology Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250
Aug 05, 2018
BioPortfolio
Encorederm: Encore Dermatology Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250
May 01, 2018
BioPortfolio
Encore Dermatology: Encore Dermatology Inc. Announces the Launch of IMPOYZTM clobetasol propionate Cream 0.025 a Newly Formulated HighPotency Topical Corticosteroid
Dec 01, 2017
Business Wire
Press Release: Encore Dermatology : Dr. Reddy's Announces Approval of Impoyz (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval
Encore Dermatology Inc Competitors
1
2
3
4
5
6
7
8
9
10